Brief: Dermapharm H1 Adjusted Group EBITDA Up 9% At EUR 149 Mln

Dermapharm Holding SE

23/08/2022 06:51

Aug 23 (Reuters) - DERMAPHARM HOLDING SE  DMPG.DE :
    * H1 ADJUSTED GROUP EBITDA INCREASES BY 9% TO EUR 149
MILLION
    * H1 CONSOLIDATED REVENUE INCREASED BY 10% TO EUR 471
MILLION
    * MANAGEMENT BOARD CONFIRMS FORECAST FOR FULL YEAR 2022
    * BROADLY DIVERSIFIED PRODUCT PORTFOLIO AS AN IMPORTANT
GUARANTEE
FOR SUCCESS
    * MANAGEMENT BOARD CONTINUES TO EXPECT GROWTH IN
CONSOLIDATED
REVENUE OF 10% TO 13%
    * EXPECTS ADJUSTED GROUP EBITDA OF 3% TO 7%, THUS CONFIRMING
FORECAST FROM APRIL 2022
    * WILL PUBLISH FINAL FIGURES FOR FIRST HALF OF 2022 WITH
FULL
HALF-YEAR FINANCIAL REPORT 2022 ON 7 SEPTEMBER 2022
    * CEO SAYS "CONSEQUENCES OF RUSSIA'S WAR OF AGGRESSION ON
UKRAINE
ARE NOW ALSO BEING CLEARLY FELT BY MANUFACTURING INDUSTRY"

Source text for Eikon:  ID:nEQ4q3PX6a 
Further company coverage:  DMPG.DE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))